awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607
Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607
Targeting the Checkpoint to Kill Cancer Cells
P2860
Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b8295315307012dc948fc2d4bc26ed8c9530fc9b
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer